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Abstract. Interleukin-33 (IL-33) is a nuclear and pleiotropic 
cytokine with regard to its cellular sources and its actions. IL-33 
is involved in the pathogenesis of brain diseases. Several factors 
account for the tumorigenicity of human gliomas, including 
cytokines and their receptors. The present study assessed the 
expression and prognostic significance of IL‑33 in human astro-
glial brain tumors. Protein levels of IL-33 were determined by 
immunohistochemistry using a tissue microarray containing 
95 human gliomas. mRNA expression data of IL-33, as well as 
of its receptors, IL-1 receptor-like 1 protein and IL-1 receptor 
accessory protein (IL1RAcP), were obtained from The Cancer 
Genome Atlas database. IL-33 protein was expressed heteroge-
neously in tumor tissue, but was, however, not detected in normal 
brain tissue. There was no differential IL-33 protein expression 
by tumor grade, while IL-33 protein expression was associated 
with inferior survival in patients with recurrent glioblastomas. 
Interrogations of the TCGA database indicated that mRNA 
expression of IL-33 and the IL-33 receptors was heterogeneous, 
and that IL-33 and IL1RAcP mRNA levels were correlated with 
the tumor grade. Elevated IL-33 mRNA levels were associated 
with the inferior survival of glioblastoma patients. Therefore, 
IL-33 may play an important role in the pathogenesis and prog-
nosis of human gliomas.
Introduction
Glioblastoma is the most common primary brain tumor, with 
an annual incidence of 3.9 cases per 100,000 individuals in 
the Canton of Zurich (1) and the most aggressive among all 
gliomas. The standard of care includes radiotherapy plus 
concomitant and maintenance temozolomide chemotherapy 
(TMZ/RT→TMZ) (2), resulting in a median survival time 
of 16 months in clinical trial populations (3). Several factors 
account for the tumorigenicity of gliomas, including muta-
tions in selected genes, the amplification of signaling pathway 
genes, and the exploitation of surrounding non-transformed 
brain cells induced to provide molecules essential for glioma 
growth and invasiveness (4,5). Among these, cytokines and 
their receptors have received significant attention (6,7). For 
instance, interleukin (IL)-1β, IL-6 and IL-8 are expressed by 
glioma cells and regulate glioma cell survival, migration and 
invasion (8,9). However, the expression and function of other 
IL-1 family members, such as IL-33, in human glioma cells 
have not been addressed in detail.
IL-33 is recognized for its pro-inflammatory role in 
inflammatory diseases of mucosal tissues, including allergic 
asthma, inflammatory bowel diseases and eosinophilic 
esophagitis (10-14), but also in rheumatoid arthritis and 
sarcoidosis (15). IL-33 signals through a heterodimeric receptor 
consisting of IL-1 receptor-like 1 protein (IL1RL1) and IL-1 
receptor accessory protein (IL1RAcP). Binding of IL-33 to 
the receptor activates nuclear factor-κB and mitogen-activated 
protein kinases, in a myeloid differentiation primary response 
gene 88-dependent manner (16-18).
IL-33 is predominantly and constitutively found in the nucleus 
of endothelial or epithelial cells of barrier tissues (17,19‑21). It 
mediates the recruitment and activation of immune cells such 
as mast cells, monocytes, eosinophils, neutrophils, dendritic 
cells and lymphocyte subsets (16,22). IL-33 can also exert 
multiple effects on non-immune cells (19-21). Beyond the 
extracellular receptor-mediated function of IL-33, these effects 
also appear to be receptor-independent. In this case, IL-33 acts 
as an intracellular repressor of transcription (12,20,21,23,24).
The role of IL-33 in the human brain is not well known. 
IL-33 levels were found to be overexpressed in the brain of 
patients with Alzheimer's disease (25) and multiple scle-
rosis (26). In the central nervous system (CNS) of mice, IL-33 
is constitutively expressed by astrocytes and endothelial 
cells (17,27), and it can be induced in astrocytes in response 
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to inflammatory and necrotic stimuli (28). Since growing 
evidence indicates that IL-33 plays a role in the maintenance 
and homeostasis of astrocytes (27‑30), it may also contribute to 
the development and progression of tumors derived from astro-
cytes. The function of IL-33 in human cancer has remained 
controversial, but elevated serum levels of IL-33 have been 
reported in malignancies such as gastric cancer, hepatocellular 
carcinoma and non-small cell lung cancer (31-33). Recently, it 
was shown that growth rate and colony formation of tumori-
genic C6 rat glioma cells were attenuated by the inhibition 
of IL-33 gene expression and that IL-33 induced migration 
in these cells (34). In the present study, the expression and 
prognostic significance of IL‑33 in gliomas was investigated.
Materials and methods
Patients. In accordance with the Institutional Review Board, 
and following the retrieval of informed consent, the surgical 
specimens and clinical records were retrieved from 95 patients 
who underwent brain tumor resection between January 2000 
and December 2009 at the Department of Neurosurgery, 
University Hospital Zurich (Zurich, Switzerland). In total, 
10 astrocytomas of World Health Organization (WHO) grade I 
(AI), 14 astrocytomas of WHO grade II (AII), 23 anaplastic 
astrocytomas (astrocytomas ofWHO grade III; AAIII) and 
48 glioblastomas were analyzed. The group of glioblastoma 
patients included 26 newly diagnosed patients and 22 patients 
with recurrent tumors. In 1 patient, primary and recurrent 
tumor specimens were obtained. All tumors were classified 
and graded according to the WHO classification of tumors 
of the central nervous system (35). Tissues of 4 patients, not 
diagnosed with brain tumors, were retrieved during autopsy 
and used as normal brain controls.
Immunohistochemistry. Immunohistochemistry was 
performed on a tissue microarray (TMA) with archival 
formalin‑fixed 4‑µm thick sections on SuperFrost slides 
(Menzel‑Glaser, Braunschweig, Germany). Deparaffinized, 
rehydrated sections were preincubated on the BondMax system 
(Leica, Mannheim, Germany) in Bond Epitope Retrieval 
Solution 2 (pH 9.0) for 30 min at 95˚C and then stained for 
IL-33 using goat anti-human IL-33 immunoglobulin (Ig)G 
(catalog no. AF3625; R&D Systems Inc., Minneapolis, MN, 
USA) at a dilution of 1:400. The specificity of IL‑33 staining 
was confirmed by negative staining with isotype-matched 
IgG (catalog no. AB‑108‑C; R&D Systems Inc.). The 
immunostaining results were assessed as the percentage of 
IL-33-positive (IL-33+) cells (nuclear staining) (21). Scoring 
was performed by one scientist in a blinded manner.
Interrogations of The Cancer Genome Atlas (TCGA) database. 
Microarray and outcome data were obtained from the glioblas-
toma data set of the TGCA network available on December 11, 
2014 (http://cancergenome.nih.gov/) (36). The gene expression 
data in this database were obtained using Affymetrix array. The 
query was based on the reporter with the highest mean geometric 
intensity for the target gene. The Affymetrix probesets used in 
the TCGA database were 209821_at for IL‑33, 205227_at for 
IL1RAcP and 234066_at for IL1RL1. The TCGA database 
used for this study contains data of 276 gliomas of different 
histologies and 8 control samples (37). Survival analysis within 
the glioblastoma data set of the TCGA database was performed 
using the Kaplan-Meier analysis module of the R2 microarray 
analysis and visualization platform (http://r2.amc.nl). The 
cut-off to segregate glioblastoma patients into two groups with 
high or low expression of the target gene was defined by the 
average expression level of the target gene.
Statistics. Progression‑free survival (PFS), overall survival (OS) 
and post-recurrence survival (PRS) curves were estimated by 
the Kaplan-Meier method and compared with the two-sided 
log‑rank test. PFS time was calculated from the date of surgery 
to the date of recurrence. OS time was measured from the date 
of first surgery to the date of mortality. PRS time was measured 
from the date of the surgery in which the tissue was obtained 
to the date of mortality. Patients without confirmed mortality 
were censored for OS and PRS at the last follow-up visit. 
Patients without documented progression were censored at the 
last follow‑up visit for PFS, PRS and OS. The Kruskal‑Wallis 
test (one-way analysis of variance for non-parametric values), in 
combination with Dunn's multiple comparison test, was used to 
compare protein or mRNA levels within groups. Survival-asso-
ciated analyses were calculated with the log-rank test. All 
statistical analyses were performed using Prism 5 (GraphPad 
Software Inc., La Jolla, CA, USA). P<0.05 was considered to 
indicate a statistically significant difference.
Results
Patient and tumor characteristics. Tissue sections of 
95 patients from a single center with newly diagnosed or recur-
rent glioma were analyzed, and the patient characteristics are 
presented in Table I. Glioblastoma patients were older (median 
age, 56.5 years) than patients diagnosed with WHO grade I 
(median age, 20 years), WHO grade II (median age, 37.5 years) 
or WHO grade III (median age, 41 years) tumors. In the group 
of WHO grade II-IV patients, males were more often affected 
than females. The median OS time in the group of glioblastoma 
patients (14 months) was worse than that for patients diagnosed 
with WHO grade III gliomas (41 months). The median OS 
time for patients with WHO grade II was 14.3 years, whereas 
the median survival time for patients diagnosed with WHO 
grade I was 22 years. The median OS time in the group of 
newly diagnosed glioblastoma patients was 10 months, while 
in the group of recurrent glioblastoma patients, the median OS 
time was 22 months. The PRS time for recurrent glioblastoma 
patients was 5 months.
IL‑33 is expressed in human gliomas and is associated with 
inferior survival in patients with recurrent glioblastoma. 
Protein levels of IL-33 were assessed by immunohistochemistry 
using a TMA (Fig. 1A and B). The TMA cores of normal brain 
tissue showed a number of IL-33-negative (IL-33-) neuronal 
cells and only very few, scattered, normal astrocytes with 
weak nuclear IL-33 expression. When captured on the TMA, 
infiltrating immune cells were negative. The IL-33 mean 
labeling indexes in the tumor cells were 13.3% [range, 0-65%; 
95% confidence interval (CI), 2.2‑28.7) for AI, 15.4% 
(range 0‑70%; 95% CI, 2.6‑28.1) for AII, 19.7% (range, 0‑60%; 
95% CI, 9.2‑30.2) for AAIII and 21.7% (range, 0‑92.5%; 
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95% CI, 13.1-30.3) for glioblastoma (Fig. 1B). Thus, the highest 
mean IL-33 labeling indexes were observed in glioblastoma, but 
these did not differ significantly from gliomas of other grades. 
When newly diagnosed and recurrent tumor samples for glioblas-
toma patients were analyzed separately, the mean percentages 
were 19.4% (range, 0-92.5%; 95% CI, 8.9-29.9) for newly 
diagnosed tumors and 24.4% (range, 0-90%; 95% CI, 9.4-39.5) 
for recurrent tumors (Fig. 1C). Based on the percentages of the 
IL-33 labeling indexes, patients were divided into two groups: 
Negative (0%) and positive (≥1%) for IL‑33. The ratios of IL‑33- 
to IL-33+ patients per WHO grade were as follows: AI, 50/50; 
AII, 57/43; AAIII, 57/43; and glioblastoma, 48/52. Nuclear IL-33 
was also regularly found in endothelial cells of vessels that were 
randomly captured on TMA cores of tumor and normal brain 
tissues (data not shown).
To search for an association between IL-33 labeling indexes 
and survival, patients with glioblastoma were divided into 
two groups, defined as positive or negative for this cytokine. 
Patient characteristics of IL-33- or IL-33+ patients separated 
for newly diagnosed or recurrent tumors are summarized 
in Table II. In the group of newly diagnosed glioblastomas 
(n=26), the median age was 63 years in the IL-33- group and 
57 years in the IL‑33+ group. There was a male predominance 
in the group of IL-33- patients. The pre-operative Karnofsky 
performance score (KPS) was similar in the two groups. 
Treatment regimes in the groups differed: While the majority 
of IL-33- patients had received TMZ/RT→TMZ (66.7%), the 
majority of IL-33+ patients had received RT only (42.9%) or 
TMZ/RT (21.4%), due to early tumor progression (Table II). 
The median PFS time was 6 months for the IL‑33- patients 
and 3 months for the IL-33+ patients (P=0.709) (Fig. 1D). The 
OS time was 13 months for the IL-33- patients and 9 months 
for the IL-33+ patients (P=0.815) (Fig. 1E). In the recurrent 
glioblastoma group (n=22), the median age was 50 years 
in the IL-33- group and 59 years in the IL-33+ group. The 
pre-operative KPS was similar in the two groups. Prior to 
second surgery, the majority of IL-33- patients had received 
TMZ/RT→TMZ (27.3%) or RT→TMZ (27.3%), whereas the 
group of IL-33+ patients received TMZ/RT→TMZ (54.5%) 
(Table II). In total, 45.5% of the recurrent patients in each 
group, IL-33+ or IL-33-, received TMZ alone as post-surgery 
treatment at the time of recurrence (Table II). The median PFS 
time was 13 months for the IL-33- patients and 6 months for 
the IL-33+ patients (P=0.308) (Fig. 1D). The median OS time 
was 34 months for the IL-33- patients and 14 months for the 
IL-33+ patients (P=0.045) (Fig. 1E). The median PRS time was 
10 months for the IL-33- patients and 4 months for the IL-33+ 
patients (P=0.026) (Fig. 1F).
IL‑33 expression in human gliomas: An analysis of the TCGA 
database. Microarray data were acquired from the TCGA 
database (36) and a glioma population (37), including AI 
(n=8), AII (n=24), AAIII (n=85) and glioblastoma (n=159) 
samples selected for validation of IL-33 expression and its 
prognostic significance. Another 8 normal brain samples 
were included. The median mRNA expression levels of 
IL-33 were 6.2 (95% CI, 5.3-6.9) for normal brain tissues, 
6.8 (95% CI, 5.31‑6.85) for AI, 7.3 (95% CI, 6.5‑7.5) for AII, 
6.4 (95% CI, 5.8‑6.6) for AAIII and 7.0 (95% CI, 6.7‑7.1) for 
glioblastoma (Fig. 2A). The median IL-33 mRNA expression 
levels varied significantly (P=0.02), but multiple comparisons 
between each tumor grade did not demonstrate statistically 
significant results (Fig. 2A).
Next, the IL-33 receptors, IL1RL1 and IL1RAcP, 
were analyzed. The median mRNA expression levels of 
IL1RL1 were 6.2 (95% CI, 5.3-6.9) for normal brain tissues, 
6.8 (95% CI, 5.31‑6.85) for AI, 7.3 (95% CI, 6.5‑7.5) for AII, 
6.4 (95% CI, 5.8‑6.6) for AAIII and 7.0 (95% CI, 6.7‑7.1) for 
glioblastoma (Fig. 2B). mRNA levels were not increased or 
decreased in any of the analyzed groups compared with each 
Table I. Patient characteristics.
 WHO grade
 -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 I II III IV IV nd IV rec
Characteristic (n=10) (n=14) (n=23) (n=48) (n=26) (n=22)
Age at diagnosis, years      
  Median 20.0 37.5 41.0 56.5 58.5 53.0
  Range 1‑29 23‑69 24‑75 18‑80 21‑80 18‑79
Gender, n      
  Female  5   4 10 15 10   5
  Male 5 10 13 33 16 17
Survival, months (events)      
  Median OS 264 (2) 172 (3) 41 (12) 14 (39) 10 (21) 22 (18)
    (95% CI) ‑ ‑ ‑ (2.9‑7) (2.9‑6) (3‑14.2)
  Median PRS n. a. n. a. n. a. n. a. n. a. 5 (18)
    (95% CI)      (4.0-10.1)
WHO grades I-IV correspond with AI, AII, AAIII and glioblastoma tumors, respectively. WHO, World Health Organization; events, number of 
patients with confirmed death; OS, overall survival; PRS, post‑recurrence survival; CI, confidence interval; nd, newly diagnosed; rec, recurrent; 
n.a., not applicable.
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other. By contrast, the median IL1RAcP mRNA levels were 
increased in the glioblastoma patients compared with that of 
the patients diagnosed with AII (P<0.01) or AAIII (P<0.01). 
The median mRNA expression levels of IL1RAcP were 
5 (95% CI, 4.6‑5.3) for normal brain tissues, 8.4 (95% CI, 7.1‑8.9) 
for AI, 5.7 (95% CI, 5.3‑6.4) for AII, 6.6 (95% CI, 6.4‑7.1) for 
AAIII and 7.9 (95% CI, 7.6‑8) for glioblastoma (Fig. 2C). A 
correlation in mRNA expression levels was found between 
IL-33 and IL1RAcP (r=0.14, P=0.02), but not between IL-33 
and IL1RL1 (r=0.08, P=0.20). There were no correlations 
between the IL‑33 receptors (r=‑0.04, P=0.52) (Fig. 2D). 
Finally, microarray and outcome data for glioblastoma were 
obtained from the TCGA database. Patients were divided into 
two groups with high or low IL-33 mRNA expression. The 
cut‑off was defined by the average mRNA expression level of 
the target gene. Patients with higher IL-33 mRNA expression 
Figure 1. IL‑33 protein labeling in human gliomas. (A) Representative tissue sections demonstrating no nuclear staining of IL‑33 in normal brain tissues, but 
strong nuclear staining in glioblastoma. (B) The percentage of IL-33 nuclear-positive cells was assessed by immunohistochemistry of human normal brain 
tissues (NB), World Health Organization grade I (AI), II (AII) and III astrocytomas (AAIII), and glioblastoma (grade IV astrocytomas) samples. Each tissue 
sample is indicated by a dot. The black bar marks the mean in each group. (C) The percentage of IL-33 nuclear-positive cells was assessed in nd and rec 
glioblastomas. (D) Progression‑free survival and (E) overall survival are shown in nd (left) and rec (right) patients. (F) Post‑recurrence survival data. IL‑33+ 
patients were compared with IL-33- patients (P<0.05 was considered significant). IL‑33, interleukin‑33; n.s., not significant; nd, newly diagnosed; rec, reccur-
rent; IL-33+, IL-33-positive; IL-33-, IL-33-negative.
  A
  B   C
  D
  F
  E
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Table II. Clinical characteristics, treatment and outcome in human glioblastoma by IL-33 protein labeling indexes.
 Newly diagnosed Recurrent
 ---------------------------------------------------------------- --------------------------------------------------------------
 IL-33- IL-33+ IL-33- IL-33+
Characteristic (n=12) (n=14) (n=11) (n=11)
Age, years    
  Median 63 57 50 59
  Range 21‑77 41‑80  21‑63 18‑79 
Age groups, n (%)    
  ≤40 years 1 (8.3) 0 (0.0)   3 (27.3)   3 (27.3)
  41‑50 years   2 (16.7)   4 (28.6)   3 (27.3) 0
  51‑60 years   3 (25.0)   4 (28.6)   3 (27.3)   4 (36.4)
  61‑70 years 1 (8.3)  3 (21.4)   2 (18.2)   3 (27.3)
  >70 years   5 (41.7)   3 (21.4) 0 (0.0) 1 (9.1)
Gender, n (%)    
  Female 1 (8.3)   9 (64.3) 1 (9.1)   4 (36.4)
  Male 11 (91.7)   5 (35.7) 10 (90.9)   7 (63.6)
KPS (pre-operative), n (%)    
  90‑100 1 (8.3) 1 (7.1)   5 (45.5)   3 (27.3)
  70‑80   8 (66.7) 11 (78.6)   5 (45.5)   7 (63.6)
  <70   3 (25.0)   2 (14.3) 1 (9.1) 1 (9.1)
Tumor localization, n (%)    
  Frontal   2 (16.7)   3 (21.4) 1 (9.1)   4 (36.4)
  Parietal 0 (0.0)   2 (14.3)   3 (27.3) 0 (0.0)
  Temporal   3 (25.0)   7 (50.0)   5 (45.5)   5 (45.5)
  Occipital 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
  Brainstem 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
  Cerebellar 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
  Spinal 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
  Multifocal (>2 regions)   5 (41.7)   2 (14.3)   2 (18.2)   2 (18.2)
Surgery, n (%)    
  Biopsy 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
  Partial resection   2 (16.7)   2 (14.3) 1 (9.1)   2 (18.2)
  Subtotal resection   9 (75.0)   2 (14.3)   3 (27.3)   6 (54.5)
  Gross total resection 1 (8.3) 10 (71.4)   7 (63.6)   2 (18.2)
  No data 0 (0.0) 0 (0.0) 0 (0.0) 1 (9.1)
First‑line therapy, n (%)    
  No therapy   2 (16.7)   2 (14.3) 1 (9.1)   2 (18.2)
  RT alone 1 (8.3)   6 (42.9)   2 (18.2) 1 (9.1)
  RT→TMZ   3 (25.0) 1 (7.1)   3 (27.3)   2 (18.2)
  TMZ/RT 0 (0.0)   3 (21.4)   2 (18.2) 0 (0.0)
  TMZ/RT→TMZ   8 (66.7) 1 (7.1)   3 (27.3)   6 (54.5)
  TMZ alone 0 (0.0) 1 (7.1) 0 (0.0) 0 (0.0)
  No data 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0)
Post-second or -third surgery     
treatmenta, n (%)    
  No therapy     2 (18.2) 1 (9.1)
  TMZ/RT→TMZ   1 (9.1) 1 (9.1)
  TMZ alone     5 (45.5)   5 (45.5)
  Lomustine alone n. a. n. a.   2 (18.2) 0 (0.0)
  Gefitinib alone   0 (0.0) 1 (9.1)
  Bevacizumab plus irinotecan   0 (0.0)   2 (18.2)
  No data   1 (9.1) 1 (9.1)
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Table II. Continued.
 Newly diagnosed Recurrent
 ------------------------------------------------------------------ -------------------------------------------------------------
 IL-33- IL-33+ IL-33- IL-33+
Characteristic (n=12) (n=14) (n=11) (n=11)
Survival 
  Median follow‑up, months 12 7.5 27 14
  Median PFS, months (events)   6 (11) 3 (13)   13 (11)   6 (11)
    (95% CI) (1.9‑8.9) (0.9‑5) (3‑27.9) (3‑12)
  Median PRS, months (events) n.a. n.a. 10 (7)   4 (11)
    (95% CI)   (3.9-54.9) (-)
  Median OS, months (events) 13 (11) 9 (10) 34 (7) 14 (11)
    (95% CI) (1.9-19.8) (3.8-11.9) (9.9-30.5) (-)
  Alive at last follow up, n (%) 1 (8.3) 4 (28.6) 4 (36.4) 0 (0.0)
aData are reported from the date of the surgery in which the tissue was obtained. IL‑33, interleukin‑33; TMZ, temozolomide; PFS, progression-free 
survival; PRS, post‑recurrence survival; OS, overall survival; events, number of patients with confirmed progression or death; CI, confidence 
interval; RT, radiotherapy; -, negative; +, positive; n. a., not applicable; KPS, Karnofsky performance score. TMZ/RT→TMZ, radiotherapy 
plus concomitant and maintenance temozolomide chemotherapy.
 
Figure 2. IL‑33 mRNA expression in human gliomas: An analysis of The Cancer Genome Atlas (TCGA) network. (A) Interleukin‑33 (IL‑33), (B) IL‑1 
receptor-like 1 protein (IL1RL1) and (C) IL-1 receptor accessory protein (IL1RAcP) mRNA expression levels of normal brain (NB), World Health Organization 
grade I (AI), II (AII) and III astrocytomas (AAIII), and glioblastomas (grade IV astrocytomas) were obtained from the TCGA database. Box plots are shown 
(median, range). Values are represented in a logarithmic scale. P-values were assessed using the Kruskal Wallis test. (D) Pairwise correlation was assessed 
among mRNA data of IL‑33, IL1R1 and IL1RAcP. Two‑tailed Spearman test coefficients (r) and significances (p) are indicated. Values are represented in a 
logarithmic scale. (E) Kaplan-Meier survival curves of overall survival are shown for the group of glioblastoma patients. Patients were divided into two groups 
with high (blue line) vs. low (red line) IL‑33 mRNA expression. The cut‑off was defined by the average mRNA expression level of the target for glioblastoma. 
Target genes were IL‑33, IL1RL1 or IL1RAcP (P<0.05 was considered significant). *P<0.05; **P<0.01; ***P<0.001; n.s., not significant.
  A   B   C
  D
  E
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levels experienced inferior survival (P=0.016). IL1RL1 and 
IL1RAcP mRNA expression levels were not associated with 
survival in the group of glioblastoma patients (Fig. 2E).
Discussion
Members of the IL-1 family (e.g., IL-1β, IL-6 and IL-8) are 
expressed by glioma cells and modulate survival, migration 
and invasion (8). IL-33, another IL-1 family member, is a 
pleiotropic cytokine that may be involved in the pathogenesis 
of brain diseases (38). IL‑33 is a pro‑inflammatory mediator 
activating microglia, and inducing inflammatory cytokines and 
chemokines, and thus may have neuroprotective or neurotoxic 
effects depending on tissue conditions. In a previous study, the 
increased expression of IL-33 contributed to enhanced cell 
growth of rat glioma cells and the invasion of microglia (34). 
Moreover, exogenously administrated IL-33 enhanced primary 
tumor growth and inhibited innate antitumor immunity in a 
metastatic breast cancer model (39).
The purpose of the present study was to assess IL-33 
expression in human astroglial brain tumors and to evaluate its 
prognostic significance. Normal brain sections were found to 
be negative for IL-33 protein expression. The high level IL-33 
detection in certain astrocytomas suggested a pathogenetic role 
for this cytokine (Fig. 1B). On the other hand, similar levels 
of IL-33 across all WHO grades showed IL-33 production 
to be independent of the grade of malignancy. Furthermore, 
protein levels of IL-33 were markedly similar among newly 
diagnosed and recurrent glioblastomas, indicating that treat-
ment in this patient population does not significantly affect 
its expression (Fig. 1C). IL‑33 protein labeling indexes were 
not associated with PFS in the glioblastoma patients (Fig. 1D). 
However, in the subgroup of recurrent glioblastoma patients, 
IL-33+ tumors demonstrated inferior OS and PRS compared 
with IL-33- tumors (Fig. 1E and F). This could indicate that 
IL-33 expression may be an important feature for advanced 
glioblastoma patients. In line with these indications, IL-33 
is known to enhance tumor surveillance and antitumor 
immunity (40,41). Therefore, IL-33 may contribute to tumor 
progression and antitumor activity, depending on the levels of 
IL-33 and the microenvironment. The microenvironment of 
gliomas in situ comprises not only stromal CNS-intrinsic cell 
types, such as astrocytes and microglial cells, but also inflam-
matory cells that have infiltrated into the tumor from the 
circulation, including lymphocytes, macrophages, neutrophils 
and eosinophils (42,43). Although these infiltrating immune 
cells may seek to curb tumor growth initially, evidence points 
to the tumor subsequently affecting the immune cells to allow 
its growth. Necrosis or inflammation in the CNS causes the 
release of IL-33, particularly from astrocytes and glioma 
cells. However, since there is a population of resident mast 
cells in the CNS (44,45), it would also lead to the secretion of 
IL-33 by the mast cells. This could have profound effects in 
glioma progression since IL-33 may then in turn act not only 
on astrocytes, but also on tumor cells and possibly other CNS 
glial cells to induce STAT6-responsive genes to complete an 
important, neural-immune circuit (46).
TCGA interrogation in the present study indicated that 
the mRNA levels of IL-33, as well as those of IL1RAcP, are 
upregulated in human glioblastoma (Fig. 2A and C), and that 
IL-33 mRNA expression correlates with IL1RAcP mRNA 
expression (Fig. 2D), suggesting that there may be an IL‑33 
autocrine loop in CNS tumors derived from glial cells, partic-
ularly astrocytes (28). TCGA also made it possible to delineate 
an association between IL-33 mRNA expression and inferior 
survival in glioblastoma patients (Fig. 2E), suggesting that the 
IL‑33‑expressing phenotype defines a glioma subset with a 
more aggressive course and a worse prognosis.
Angiogenesis is another hallmark of glioblastoma. Notably, 
Choi et al demonstrated that IL-33 promotes angiogenesis and 
vasopermeability in vivo and in vitro (47). Endothelial cells 
are a source of IL-33 and also express the heterodimeric 
IL1RL1 (27). In the present study, IL‑33 was not expressed 
in all endothelial cells of normal brain and intra-/peritumoral 
glioma vessels, but this could not be addressed systematically 
since vessels were not captured on all TMA cores, and the 
TMA was designed to study tumor tissues. The TMA-based 
approach allowed for large-scale analysis of multiple human 
glioma cases. However, the approach is by nature limited to 
the study of IL-33 expression in the tumor area selected on the 
TMA. Therefore, a systematic evaluation of different tumor 
subregions (e.g., necrotic or vascular areas) was not possible.
The present study data suggested that IL-33 may play a 
role in human glioma development, growth and progression. 
This could be due to IL-33-mediated communication between 
glioma cells and components of the tumor microenvironment, 
such as resident astrocytes, microglia and inflammatory 
or endothelial cells. Alternatively, IL-33 overexpression in 
glioma could be a bystander effect reflecting a more general 
disease-associated phenomenon, as IL-33 is upregulated 
in other neurological conditions as well (48). The complex 
interactive network of IL-33 and the extent to which the 
IL-33/IL1RL1/IL1RAcP axis can be affected by therapeutic 
intervention will require elucidation in human glioma.
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